AKBA — Akebia Therapeutics Share Price
0.000.00%
Last trade - 00:00- $594.64m
- $581.46m
- $160.18m
- 30
- 30
- 84
- 46
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.71 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.48% | ||
| Return on Equity | n/a | ||
| Operating Margin | -31.83% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 294.64 | 211.65 | 292.48 | 194.62 | 160.18 | 192.37 | 275.54 | -13.72% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Directors
- Adrian Adams NEC (70)
- John Butler PRE (56)
- David Spellman CFO (44)
- Michel Dahan COO (42)
- Nicole Hadas SVP (48)
- Steven Burke SVP (60)
- Dell Faulkingham SVP (48)
- Ron Frieson IND
- Steven Gilman IND (68)
- Michael Heffernan IND (56)
- Michael Rogers IND (61)
- Cynthia Smith IND (52)
- Myles Wolf IND (50)
- LeAnne Zumwalt IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 27th, 2007
- Public Since
- March 20th, 2014
- No. of Shareholders
- 26
- No. of Employees
- 181
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 249,848,992
- Address
- 245 First Street, CAMBRIDGE, 02142
- Web
- https://akebia.com/
- Phone
- +1 6178712098
- Auditors
- Ernst & Young LLP
Upcoming Events for AKBA
Akebia Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Akebia Therapeutics Inc Earnings Release
Similar to AKBA
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
Assertio Holdings
NASDAQ Capital Market
FAQ
What is the Akebia Therapeutics share price?
As of Today at 19:10 UTC, shares in Akebia Therapeutics are trading at $2.38. This share price information is delayed by 15 minutes.
How has the Akebia Therapeutics share price performed this year?
Shares in Akebia Therapeutics last closed at $2.38 and the price had moved by +78.95% over the past 365 days. In terms of relative price strength the Akebia Therapeutics share price has outperformed the S&P500 Index by +65.17% over the past year.
What are the analyst and broker recommendations for Akebia Therapeutics?
The overall consensus recommendation for Akebia Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Akebia Therapeutics dividend yield?
Akebia Therapeutics does not currently pay a dividend.
Does Akebia Therapeutics pay a dividend?
Akebia Therapeutics does not currently pay a dividend.
When does Akebia Therapeutics next pay dividends?
Akebia Therapeutics does not currently pay a dividend.
How do I buy Akebia Therapeutics shares?
To buy shares in Akebia Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Akebia Therapeutics?
As of the previous close price of $2.38, shares in Akebia Therapeutics had a market capitalisation of $594.64m.
Where are Akebia Therapeutics shares listed?
Here are the trading details for Akebia Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AKBA
What kind of share is Akebia Therapeutics?
Based on an overall assessment of its quality, value and momentum Akebia Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Akebia Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Akebia Therapeutics is $7.38. That is 210.08% above the last closing price of $2.38.
Analysts covering Akebia Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.19 for the next financial year.
Find out moreWhat is the trend in the Akebia Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Akebia Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +57.77%.
As of the last closing price of $2.38, shares in Akebia Therapeutics were trading +36.85% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Akebia Therapeutics PE Ratio?
The Akebia Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Akebia Therapeutics?
Akebia Therapeutics' management team is headed by:
- Adrian Adams - NEC
- John Butler - PRE
- David Spellman - CFO
- Michel Dahan - COO
- Nicole Hadas - SVP
- Steven Burke - SVP
- Dell Faulkingham - SVP
- Ron Frieson - IND
- Steven Gilman - IND
- Michael Heffernan - IND
- Michael Rogers - IND
- Cynthia Smith - IND
- Myles Wolf - IND
- LeAnne Zumwalt - IND